Australian state government announces medicinal cannabis trial

53.85% credibility
 
Related

Japan s Cat Island Asks Internet For Food, Gets More Than They Can Store

Stuff
604 points

The schoolboy, 16, who will live with a Russian porn star in a hotel for a month

Stuff
3964 points



Most recent

Celebra un Magnifique Mother s Day con el Cacao Brunch de Sofitel Bogotá Victoria Regia

Negocios Hoy
6 points

Nueva alarma sobre otro efecto del cambio climático: los virus saltan de animales a personas

NOTICIAS-ETF
8 points

ETEK incorpora a Juan Carlos Aponte para liderar el equipo comercial de Bogotá

Negocios Hoy
6 points

Consejos de Kingston para elegir la opción de almacenamiento externo adecuada

Turismo&Tecnología
8 points

El motorola edge 30 pro llega a Colombia: #FindYourEdge

TECH2022
10 points

GM Sectec y UPR Río Piedras firman convenio enfocado en la seguridad cibernética

Comms1
10 points

Arranca el 024 con el objetivo de reducir la cifra de suicidios

NOTICIAS-ETF
8 points

Mi agradecimiento a los músicos: El coronavirus

El diario de Enrique
12 points

El deshielo extremo en la Antártida develó una isla nunca antes vista en el Polo Sur

NOTICIAS-ETF
112 points

Museo Moco Barcelona ¿Merece la pena? Arte moderno y contemporáneo

mihotelperfecto.com
8 points
SHARE
TWEET
The New South Wales (NSW) state government announced on Tuesday, Oct. 27, it would begin trials of cannabis-based medicines for children with severe epilepsy starting next year, subject to ethical approval.

Australian state government announces medicinal cannabis trial

In a statement released by NSW's Premier, Mike Baird, the government says it will partner with a British-based pharmaceutical company, GW Pharmaceuticals, to facilitate the trial with researchers in the Sydney Children's Hospital Network.

"This confirms NSW’s position as a world leader on medicinal cannabis and demonstrates the determination of our Government to ensure we secure these groundbreaking trials," Baird said. "Our research and development is driven by compassion for those suffering so we hope that these initiatives will bring relief to many children and their loved ones."

The announcement outlines a commitment of A$3.5 million dollars (US$4.8 million) to research cannabis-based medicinal products for help with treating drug-resistant epilepsy.

The main focus will be on cannabinoid cannibidivarin (CBDV), a molecule in the cannabis plant that has shown promising results as an anti-convulsant. It does not produce psychoactive effects and has already been tested in adults.

“The phase 1 testing was carried out in healthy adults with no significant side effects, and we’re now ready to progress to phase 2 in children and have chosen to do this in NSW,” GW's CEO Justin Gover said in the statement.

University of NSW researcher, Roy Beran, said the ideal focus for the trial would be on a rare form of the disorder known as Dravet syndrome, according to the Southern Courier.

Dravet Syndrome, according to the Dravet Foundation, is an epilepsy condition that begins in infancy and is something that children cannot grow out of. It causes behavioral and developmental delays, orthopedic conditions, chronic infections and much more.

The deal will also involve a compassionate access scheme for those too sick to participate in a clinical trial, with the GW drug Epidiolex. It is a liquid formulation of pure plant-derived Cannabidiol (CBD) and is currently in late-stage trials in the U.S.

National sentiment for legalisation of medicinal cannabis is strong, with polls from market research company Roy Morgan showing 91 percent of Australians support the move.

The announcement follows a year of rife debate on the topic of legalising medicinal marijuana in the country, with the federal government recently announcing plans to legalise growing the plant for scientific purposes.

Fuente: mashable.com
SHARE
TWEET
To comment you must log in with your account or sign up!
Featured content